These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 12651161

  • 1. Roles of mitogen-activated protein kinase and phosphoinositide 3'-kinase in ErbB2/ErbB3 coreceptor-mediated heregulin signaling.
    Vijapurkar U, Kim MS, Koland JG.
    Exp Cell Res; 2003 Apr 01; 284(2):291-302. PubMed ID: 12651161
    [Abstract] [Full Text] [Related]

  • 2. Mutation of a Shc binding site tyrosine residue in ErbB3/HER3 blocks heregulin-dependent activation of mitogen-activated protein kinase.
    Vijapurkar U, Cheng K, Koland JG.
    J Biol Chem; 1998 Aug 14; 273(33):20996-1002. PubMed ID: 9694850
    [Abstract] [Full Text] [Related]

  • 3. Heregulin-dependent activation of phosphoinositide 3-kinase and Akt via the ErbB2/ErbB3 co-receptor.
    Hellyer NJ, Kim MS, Koland JG.
    J Biol Chem; 2001 Nov 09; 276(45):42153-61. PubMed ID: 11546794
    [Abstract] [Full Text] [Related]

  • 4. Phosphoinositide 3-kinase signaling is critical for ErbB3-driven breast cancer cell motility and metastasis.
    Smirnova T, Zhou ZN, Flinn RJ, Wyckoff J, Boimel PJ, Pozzuto M, Coniglio SJ, Backer JM, Bresnick AR, Condeelis JS, Hynes NE, Segall JE.
    Oncogene; 2012 Feb 09; 31(6):706-15. PubMed ID: 21725367
    [Abstract] [Full Text] [Related]

  • 5. Functional interaction between mouse erbB3 and wild-type rat c-neu in transgenic mouse mammary tumor cells.
    Kim A, Liu B, Ordonez-Ercan D, Alvarez KM, Jones LD, McKimmey C, Edgerton SM, Yang X, Thor AD.
    Breast Cancer Res; 2005 Feb 09; 7(5):R708-18. PubMed ID: 16168116
    [Abstract] [Full Text] [Related]

  • 6. A naturally occurring secreted human ErbB3 receptor isoform inhibits heregulin-stimulated activation of ErbB2, ErbB3, and ErbB4.
    Lee H, Akita RW, Sliwkowski MX, Maihle NJ.
    Cancer Res; 2001 Jun 01; 61(11):4467-73. PubMed ID: 11389077
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Suppression of heregulin β signaling by the single N-glycan deletion mutant of soluble ErbB3 protein.
    Takahashi M, Hasegawa Y, Ikeda Y, Wada Y, Tajiri M, Ariki S, Takamiya R, Nishitani C, Araki M, Yamaguchi Y, Taniguchi N, Kuroki Y.
    J Biol Chem; 2013 Nov 15; 288(46):32910-21. PubMed ID: 24097984
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway.
    St-Laurent V, Sanchez M, Charbonneau C, Tremblay A.
    J Steroid Biochem Mol Biol; 2005 Feb 15; 94(1-3):23-37. PubMed ID: 15862947
    [Abstract] [Full Text] [Related]

  • 11. c-Src modulates ErbB2 and ErbB3 heterocomplex formation and function.
    Ishizawar RC, Miyake T, Parsons SJ.
    Oncogene; 2007 May 24; 26(24):3503-10. PubMed ID: 17173075
    [Abstract] [Full Text] [Related]

  • 12. Heregulin negatively regulates transcription of ErbB2/3 receptors via an AKT-mediated pathway.
    Awasthi S, Hamburger AW.
    J Cell Physiol; 2014 Nov 24; 229(11):1831-41. PubMed ID: 24692179
    [Abstract] [Full Text] [Related]

  • 13. HER2+ Cancer Cell Dependence on PI3K vs. MAPK Signaling Axes Is Determined by Expression of EGFR, ERBB3 and CDKN1B.
    Kirouac DC, Du J, Lahdenranta J, Onsum MD, Nielsen UB, Schoeberl B, McDonagh CF.
    PLoS Comput Biol; 2016 Apr 24; 12(4):e1004827. PubMed ID: 27035903
    [Abstract] [Full Text] [Related]

  • 14. Antitumor activity of a novel bispecific antibody that targets the ErbB2/ErbB3 oncogenic unit and inhibits heregulin-induced activation of ErbB3.
    McDonagh CF, Huhalov A, Harms BD, Adams S, Paragas V, Oyama S, Zhang B, Luus L, Overland R, Nguyen S, Gu J, Kohli N, Wallace M, Feldhaus MJ, Kudla AJ, Schoeberl B, Nielsen UB.
    Mol Cancer Ther; 2012 Mar 24; 11(3):582-93. PubMed ID: 22248472
    [Abstract] [Full Text] [Related]

  • 15. Akt-mediated survival of oligodendrocytes induced by neuregulins.
    Flores AI, Mallon BS, Matsui T, Ogawa W, Rosenzweig A, Okamoto T, Macklin WB.
    J Neurosci; 2000 Oct 15; 20(20):7622-30. PubMed ID: 11027222
    [Abstract] [Full Text] [Related]

  • 16. Autocrine heregulin generates growth factor independence and blocks apoptosis in colon cancer cells.
    Venkateswarlu S, Dawson DM, St Clair P, Gupta A, Willson JK, Brattain MG.
    Oncogene; 2002 Jan 03; 21(1):78-86. PubMed ID: 11791178
    [Abstract] [Full Text] [Related]

  • 17. The Asn418-linked N-glycan of ErbB3 plays a crucial role in preventing spontaneous heterodimerization and tumor promotion.
    Yokoe S, Takahashi M, Asahi M, Lee SH, Li W, Osumi D, Miyoshi E, Taniguchi N.
    Cancer Res; 2007 Mar 01; 67(5):1935-42. PubMed ID: 17332320
    [Abstract] [Full Text] [Related]

  • 18. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L, Cao Z, Wu X, Ingalla ER, Baron C, Young LJ, Gregg JP, Cardiff RD, Borowsky AD, Sweeney C, Carraway KL.
    Cancer Res; 2006 Dec 01; 66(23):11279-86. PubMed ID: 17145873
    [Abstract] [Full Text] [Related]

  • 19. Essential role for Rac in heregulin beta1 mitogenic signaling: a mechanism that involves epidermal growth factor receptor and is independent of ErbB4.
    Yang C, Liu Y, Lemmon MA, Kazanietz MG.
    Mol Cell Biol; 2006 Feb 01; 26(3):831-42. PubMed ID: 16428439
    [Abstract] [Full Text] [Related]

  • 20. ErbB3-ErbB2 Complexes as a Therapeutic Target in a Subset of Wild-type BRAF/NRAS Cutaneous Melanomas.
    Capparelli C, Rosenbaum S, Berman-Booty LD, Salhi A, Gaborit N, Zhan T, Chervoneva I, Roszik J, Woodman SE, Davies MA, Setiady YY, Osman I, Yarden Y, Aplin AE.
    Cancer Res; 2015 Sep 01; 75(17):3554-67. PubMed ID: 26206558
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.